Tibolone and Its Metabolites Induce Antimitogenesis in Human Coronary Artery Smooth Muscle Cells: Role of Estrogen, Progesterone, and Androgen Receptors

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 2, 2004, Pages 852-859

  Dubey, Raghvendra K ^a,b   Gillespie, Delbert G ^a   Grögli, Marion ^b   Kloosterboer, Helenius J ^c   Imthurn, Bruno ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c R and D Laboratories   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXIDE TIBOLONE; 3BETA HYDROXIDE TIBOLONE; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIESTROGEN; ANTIGESTAGEN; COLLAGEN; DELTA 4 TIBOLONE; DRUG METABOLITE; ESTROGEN RECEPTOR; FLUTAMIDE; FULVESTRANT; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROGESTERONE RECEPTOR; TIBOLONE; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; DNA SYNTHESIS; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; ENZYME PHOSPHORYLATION; FEMALE; HEART PROTECTION; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER;

ARTERIES; CELLS, CULTURED; CORONARY VESSELS; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MITOSIS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NORPREGNENES; PHOSPHORYLATION; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 1442278763     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031272     Document Type: Article

References (34)

1. Dubey RK, Jackson EK 2001 Estrogen-induced cardiorenal protection: potentialcellular, biochemical and molecular mechanisms. Am J Physiol Renal Physiol 280:F365-F388
2. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 17:288:321-333
4. Dubey RK, Gillespie DG, Zacharia LC, Imthurn B, Jackson EK 2000 Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and MAP kinase activity. Arterioscleros Thromb Vas Biol 20:964-972
5. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S 1996 Medroxyprogesterone attenuates estrogen-mediated inhibition of neo-intima formation after balloon injury of the rat carotid artery. Circulation 94:2221-2227
6. Modelska K, Cummings S 2002 Tibolone for postmenopausal women: systematic review of randomized clinical trials. J Clin Endocrinol Metab 87:16-23
7. Moore RA 1999 Livial: a review of clinical studies. Br J Obstet Gynaecol 6(Suppl 19):1-21
8. Kloosterboer HJ, Ederveen AG 2002 Pros and cons of existing treatment modalities in osteoporosis comparison between tibolone, SERMs and estrogen (+/- progestogen) treatments. J Steroid Biochem Mol Biol 83:157-165
9. Zandberg P, Peters JLM, Demacker PNM, Smit MJ, de Reeder EG, Meuleman DG 1998 Tibolone prevents atherosclerotic lesion formation in cholesterol-fed ovariectomized rabbits. Arterioscler Thromb Vasc Biol 18:1844-1854
10. Farish E, Barnes JF, Fletcher CD, Ekevall K, Calder A, Hart DM 1999 Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progestogen regimen. Menopause 6:98-104
11. Castelo-Branco C, Casals E, Figueras F, Sanjuan A, Vicente JJ, Balasch J, Vanrell JA 1999 Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behaviour of apolipoproteins AI and B. Menopause 6:92-97
12. Farish E, Fletcher CD, Hart DM, Lindsay R, Leggate J 1984 Org OD14: long-term effects on serum lipoproteins. Maturitas 6:297-299
13. Simoncini T, Genazzani AR 2000 Tibolone inhibits leukocytes adhesion molecule expression in human endothelial cells. Mol Cell Endocrinol 162:87-94
14. Mueck AO, Lippert C, Seeger H, Wallwiener D 2003 Effects of tibolone on human breast cancer cells and human vascular coronary cells. Arch Gynecol Obstet 267:139-144
15. Haenggi W, Bersinger NA, Mueller MD, Birkhaeuser MH 1999 Decrease of serum endothelin levels with postmenopausal hormone-replacement therapy or tibolone. Gynecol Endocrinol 13:202-205
16. Cicinelli E, Ignarro LJ, Galantino P, Pinto V, Barba B, Schonauer S 2002 Effects of tibolone on plasma levels of nitric oxide in postmenopausal women. Fertil Steril 78:464-468
17. Llyod GW, Patel NR, McGing EA, Cooper AF, Kamalvand K, Jackson G 1998 Acute effects of hormone replacement with tibolone on myocardial ischaemia in women with angina. Int J Clin Pract 52:155-157
18. Bjarnason NH, Bjarnason K, Haarbo J, Bennick HJ, Christiansen C 1997 Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 82:1752-1756
19. Dubey RK, Jackson EK, Rupperecht H, Sterzel RB 1997 Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. Curr Opin Nephrol Hypertens 6:88-105
20. Davies MJ, Woolf N 1993 Atherosclerosis: what is it and why does it occur? Br Heart J 69(Suppl):S3-S11
21. Erenus M, Iihan AH, Elter K 2003 Effect of tibolone treatment on intima-media thickness and the resistive indices of the carotid arteries. Fertil Steril 79:268-273
22. Dubey RK, Oparil S, Imthurn B, Jackson EK 2002 Sex hormones and hypertension. Cardiovasc Res 53:688-708
23. Timmer CJ, Verheul HAM, Doorstam DP 2002 Pharmacokinetics of tibolone in early and late postmenopausal women. Br J Clin Pharmacol 54:101-106
24. Clarkson TB, Anthony MS, Wagner JD 2001 A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab 86:5396-5404
25. Clarkson TB, Antony MS, Mikkola TS, St. Clair RW 2002 Comparison of tibolone and conjugated equine estrogens effects on carotid artery atherosclerosis of postmenopausal monkeys. Stroke 33:2700-2703
26. Force T, Bonventre JV 1998 Growth factors and mitogen-activated protein kinases. Hypertension 31(Pt 2):152-161
27. Kloosterboer HJ 2001 Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 76:231-238
28. De Gooyer ME, Kleyn GTOV, Smits KC, Ederveen AGH, Verheul HAM, Kloosterboer HJ 2001 Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 183:55-62
29. Block LJ, De Ruiter PE, Kühne ECM, Hanekamp EE, Grootegoed JA, Smid-Koopman E, Gielen SCJP, DeGooyer ME, Kloosterboer HJ, Burger CW 2003 Progestagenic effects of tibolone on human endometrial cancer cells. J Clin Endocrinol Metab 88:2327-2334
30. Gooyer de M 2003 Tibolone: possible mechanism for its tissue selectivity. PhD Thesis, Universiteit van Utrecht, Utrecht, The Netherlands: 100-109
31. Foegh M, Asotra S, Howell M, Ramwell P 1994 Estradiol inhibition of arterial neointimal hyperplasia after balloon injury. J Vasc Surg 14:722-726
32. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK 1997 Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 17:217-221
33. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK 1995 Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate: a two year follow-up study. Hypertension 25:848-853
34. Imthurn B, Rosselli M, Jaeger AW, Keller PJ, Dubey RK 1997 Differential effects of hormone replacement therapy on endogenous nitric oxide (nitrate/nitrite) levels in postmenopausal women substituted with 17β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 382:388-394